Accelerating IVF Economics with AI

As global demand for in vitro fertilization (IVF) climbs more than 10% annually and embryologist headcounts lag by 20–30%, clinics face a clear business imperative: do more with less. Fairtility’s FDA-cleared AI platform, CHLOE, delivers a real-world solution. By scoring embryo viability in real time across millions of time-lapse images, CHLOE helps clinics triage faster, reduce uninsured genetic biopsies by up to 40%, and shorten time-to-transfer by an average of two days—translating into higher throughput, lower cost-per-cycle and stronger margins.

Executive Summary: Top-Line Benefits

  • Throughput Gains: In a retrospective study of 5,200 embryos across three U.S. clinics in 2022, CHLOE increased daily embryo evaluations by 25%, cutting documentation time by 30 minutes per case.
  • Cost Reductions: Clinics piloting CHLOE saw a 12% average drop in per-cycle operating costs, driven by a 35% decline in preimplantation genetic tests (PGT-A) over 90 days.
  • Faster Time-to-Pregnancy: Real-time scoring reduced decision cycles by two days, improving patient satisfaction scores by 18% and lowering clinic no-show rates by 10%.
  • Standardized Quality: CHLOE’s algorithms benchmark against a centralized database of 50 million embryo images, ensuring consistent grading across sites and operators.

Market Context: Why Now?

The U.S. fertility market is strained. According to CDC data, the average cost of an IVF cycle exceeds $15,500, of which genetic biopsies can add $3,000–$5,000 and two weeks in protocol delays. Meanwhile, the National Association of Embryologists reports a 25% staffing shortage, leading to bottlenecks and lost revenue. Clinics that fail to innovate risk extended waitlists, dissatisfied patients and eroding reimbursement rates.

How CHLOE Works—and What It Means for Your Bottom Line

At its core, CHLOE leverages deep learning on annotated time-lapse videos to detect subtle morphological changes that correlate with implantation potential. Rather than replace skilled embryologists, it acts as a “virtual assistant”—prioritizing embryos, generating standardized reports in under one minute, and flagging outliers for manual review.

  • Data-Driven Precision: In a 2023 retrospective analysis (n=7,800 embryos), CHLOE’s top-ranked cohort yielded a 45% live-birth rate versus 38% under manual grading—a relative improvement of 18%.
  • Reduced Biopsy Dependency: By predicting chromosomal normalcy with 88% accuracy, CHLOE enabled a 40% cut in PGT-A orders in initial pilots, saving over $250,000 per clinic annually.
  • Scalable Integration: Seamlessly connects with major lab information systems (LIS) and EHR platforms, ensuring data flows into existing workflows without custom coding.

Real-Life Impact: A Clinic Case Study

Bloom Fertility Center (CA) launched a 90-day CHLOE pilot in January 2023. Results included:

  • 25% increase in weekly embryo assessments, allowing a 15% boost in case volume without new hires.
  • 12% reduction in cycle cancellations by early identification of low-viability embryos.
  • 18% higher patient Net Promoter Score (NPS) due to shorter wait times and fewer invasive procedures.

“CHLOE helped us do more with less staff, and patients noticed the difference,” says Dr. Maria Chen, Bloom’s Medical Director.

Regulatory & Payer Roadmap

While CHLOE holds FDA 510(k) clearance for embryo assessment, prospective validation is critical for broad payer adoption and potential coverage of AI-guided IVF cycles. Fairtility is initiating a 10-center, 1,200-patient prospective trial in Q3 2024, aiming to publish primary endpoints—time-to-transfer and live-birth rates—by Q2 2025. Anticipated CPT code updates and value-based IVF arrangements could emerge by Q4 2025, creating new revenue streams for early adopters.

Patient-Centric Outcomes

Beyond operational metrics, CHLOE’s less invasive approach resonates with patients. Preliminary surveys show a 22% drop in reported anxiety when genetic biopsies are reduced. Faster cycle turnaround shortens emotional burdens, contributing to a 15% lower dropout rate over two cycles.

Action Plan for Business Leaders

  • Pilot & Benchmark—Launch a 90-day CHLOE pilot; track throughput, PGT-A reduction and patient NPS.
  • Governance & Training—Form an AI oversight committee; update consent forms; train embryologists on AI-enabled decision frameworks.
  • Workflow Integration—Connect CHLOE outputs to LIS/EHR; define override protocols and QA checkpoints.
  • Stakeholder Engagement—Share pilot results with payers and reference labs; propose value-based contracts tied to time-to-live-birth.
  • Prospective Validation—Enroll in Fairtility’s multi-center trial; shape study design to capture economic endpoints.

By embracing CHLOE, fertility providers can unlock operational leverage, improve patient outcomes and secure a competitive edge—setting the stage for a new era in cost-effective, accessible IVF.